News Release
Mallinckrodt plc Announces Winners in Dublin Science Week Competition
Affirms Importance and Broadened Scope of Dublin Operation
DUBLIN--(BUSINESS WIRE)--Jan. 31, 2014--
Mallinckrodt
plc (NYSE: MNK) announced today that it has selected winners in the
annual Science Week competition. On Friday, 31st January, the
company will welcome Minister Joan Burton to its Damastown facility to
award a total of €4,000 worth of scientific equipment to the top three
entries. The competition, which this year has the theme “What Does
Chemistry Mean to Me in My Everyday Life?”, was launched in November,
2013, in conjunction with Pharmachemical Ireland and was open to
first-year students in secondary schools in the Dublin 15 / County Meath
area.
Representing Mallinckrodt and presenting the awards will be Dr. David
Keenan, recently named Vice President, Global External Manufacturing and
Managing Director of Mallinckrodt Pharmaceuticals – Ireland.
Minister Burton said: “I’m delighted to join Mallinckrodt in presenting
these awards – it’s refreshing to see an interest in science from
children at such a young age and gratifying to see a company like
Mallinckrodt supporting science programs in our schools. Over the years
Ireland has established itself as a hub for industries in the areas of
science, technology and pharmaceuticals and the natural interest in
these areas from our younger generation inspires hope that this will
continue.”
Dr. Keenan said, “I am delighted that we were able to launch these
awards as part of a larger 20th anniversary celebration of
our manufacturing presence in Ireland, and gratified by the support and
interest shown by Minister Burton. These are exciting times at
Mallinckrodt as we position ourselves to be a top quartile speciality
pharmaceutical company. I am pleased to take on the leadership role of
our Global External Manufacturing efforts here in Ireland, which is an
indication of the strategic value we see in our presence here. As
Mallinckrodt grows, our external manufacturing strategy will become
increasingly important as we identify and leverage strategic partners
and technologies to enhance value.”
In Damastown, Mallinckrodt employs more than 100 individuals in its
Principal Executive Office and Manufacturing Facility. The
82,000-square-foot, state-of-the-art facility has produced ioversol, a
bulk active pharmaceutical ingredient for contrast media, since 1993.
Mallinckrodt was formed in January 2013, to hold the pharmaceuticals
business of its former parent, and was spun off from its parent on June
28, 2013.
About Mallinckrodt
Mallinckrodt is a global specialty pharmaceutical business that
develops, manufactures, markets and distributes specialty pharmaceutical
products and medical imaging agents. The company’s Specialty
Pharmaceuticals segment includes branded and generic drugs and active
pharmaceutical ingredients, and the Global Medical Imaging segment
includes contrast media and nuclear imaging agents. Mallinckrodt has
approximately 5,500 employees worldwide and commercial presence in
roughly 70 countries. The company’s fiscal 2013 revenue totaled $2.2
billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Source: Mallinckrodt
Mallinckrodt
Lynn Phillips, 314-654-3263
Manager, Media
Relations
lynn.phillips@mallinckrodt.com
or
Hume
Brophy
Carl Gibney, 086.045.9555
or
Conall McDevitt,
00.44.787.248.65.72
or
Mallinckrodt
John Moten,
314-654-6650
Vice President, Investor Relations
john.moten@mallinckrodt.com
